216 results about "Vein injection" patented technology

A drug administration system includes a cradle attached about an intravenous injection port having a flange extending therefrom. The cradle supports first drug administration information in the nature of machine and human readable code, for example, barcode. A syringe including a needle includes a flange extending from the syringe. The syringe supports second drug administration information in machine and / or human readable form. A scanner module is constructed to slidably receive the flange of the cradle and syringe whereby the syringe needle is aligned with the intravenous injection port. The module may be provided with an electronic scanning system for identifying the first and second drug administration information, as well as determining the amount of the drug being administered from the syringe to the injection port by monitoring movement of the syringe plunger. The information and data may be stored within the module for uploading to a remote location.

Kits, apparatus, devices and methods for treating varicose veins caused by an incompetent venous junction (e.g., the saphenofemoral and / or saphenopopliteal junctions) are disclosed. The kits may include a sheath, a vein closure device, and an injection device. Alternatively, a vein closure device may include an integral injection channel and injection device. Methods may include injecting a vein with a sclerosing agent through a needle that extends in a direction that is not aligned with a longitudinal axis of a sheath or shaft.

An improved injection site (12) for infusion of parenteral fluids and the like is provided, having a pressure-actuated valve (20) and a novel split septum unit (24), which effectively prevent reflux of blood into the assembly (10). The septum unit (24) includes a resilient split septum body (64) which is precompressed so that the septum body (64) is caused to protrude proximally (78) upon insertion of a cannula (16). Consequently, upon removal of the cannula (16), there is essentially no “drumming” or creation of friction-induced negative pressures sufficient to generate blood reflux. The preloaded septum body (64) also has its proximal surface (74) essentially flush and coplanar with the adjacent proximal end (66b) of the tubular septum holder (66) to enhance the cleanliness of the unit (24). The specialized well (46) and septum unit (24) afford a resilient seal between the periphery of the septum body (64) and the surface (50), and a separate hard-surface seal between the outer margin of the surface (50) and the septum holder (66).

A tip of a needle is inserted into large vein of a patient. The needle is mounted in a butterfly device axially engaged to a generally cylindrical housing containing a Y-connector. A pharmaceutically acceptable solution is fed to the needle through the Y-connector to the housing. A quartz optic fiber is fed through the housing and needle to the tip of the needle in the patient's venous system. A source of UV and visible light directs both UV and visible light alternatively through the optic fiber to the patient's venous system to kill pathogens in the venous system.

Apparatus and methodology are disclosed for entrapping a used intravenous needle in a needle trap and removing the needle and the trap from a catheter tube so as to avoid risk of injury to both the patient and the medical attendant.

A system and method are provided for determining intravenous blood levels of a target compound contained in a blood vessel of a patient. The method includes the operation of detecting concentrations of the target compound within a patient's blood using a sensor device configured to optically test blood at a location within the blood vessel. Another operation is calculating a measured amount of a therapeutic compound to administer into the patient's bloodstream based on the concentrations of the target compound in the blood. The measured amount of therapeutic compound may then be pumped through the catheter into the patient's blood.

The present invention provides an arm model apparatus for intravenous injection training, comprising: an arm model having an insertion grooved recess formed on a top thereof, the arm model being formed such that the arm model are twisted so as to allow the back of a hand part and a cubital fossa to be oriented upwardly; a skin pad detachably mounted into the insertion grooved recess and having a blood vessel-imitating tube formed therein; a pump drive unit connected to the a blood vessel-imitating tube by a pad connecting tube; and a liquid blood supply container connected to the pump drive unit by a container connecting tube and configured to supply blood stored therein to the blood vessel-imitating tube. The inventive arm model apparatus implements a realistic skin sensation as if a syringe needle penetrated through the blood vessel of the human body through the arm model.

An improved injection site (12) for infusion of parenteral fluids and the like is provided, having a pressure-actuated valve (20) and a novel split septum unit (24), which effectively prevent reflux of blood into the assembly (10). The septum unit (24) includes a resilient split septum body (64) which is precompressed so that the septum body (64) is caused to protrude proximally (78) upon insertion of a cannula (16). Consequently, upon removal of the cannula (16), there is essentially no “drumming” or creation of friction-induced negative pressures sufficient to generate blood reflux. The preloaded septum body (64) also has its proximal surface (74) essentially flush and coplanar with the adjacent proximal end (66b) of the tubular septum holder (66) to enhance the cleanliness of the unit (24). The specialized well (46) and septum unit (24) afford a resilient seal between the periphery of the septum body (64) and the surface (50), and a separate hard-surface seal between the outer margin of the surface (50) and the septum holder (66).

An intravenous injection site having a split septum assembly interfit with the site for the intravenous administration of fluids to a patient. The split septum assembly has a resilient and compressible split septum having an axially-formed slit for receipt of a blunt cannula, needle, or other medical device through said slit, a septum holder for receipt of the split septum, and a septum housing for receipt of the combined septum holder and split septum. The septum includes a body and a flange extending radially from the body. A projection extends from the flange. The septum is mounted within the septum holder, and the septum holder is mounted within the septum housing to provide axial compression of the flange. This axial compression presents a double hermetic seal that significantly minimizes or prevents proximal leakage of fluid through the slit or around the septum holder when the cannula is removed.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the novel medical usage of icaritin, in particular to the usage of icaritin in preparation of medicine for preventing and treating endotoxemia. Lipopolysaccharide (LPS) is used for stimulating the macrophage system RAW264.7 of a mouse and establishing an extraneous endotoxic inflammation model, LPS is used for stimulating the C57BL / 6J mouse and establishing the endotoxemia animal model, icaritin is adopted for intervention, and dexamethasone is used as reference. The experiment result shows that the icaritin can reduce the death rate, the level of the inflammatory factor, the inflammatory mediator and the adhesion molecules and infiltration of inflammatory cells of the tissue after the mouse is attacked by endotoxin, and proves that the icaritin can effectively prevent and treat endotoxemia and can be used for further preparing effective drug for preventing and treating endotoxemia, including dosage forms such as oral and enteric capsules or intravenous injections.

The invention relates to a long-circulating liposome capable of avoiding an accelerated blood clearance (ABC) phenomenon, a medicine preparation containing the long-circulating liposome, and a preparation method and an application of the long-circulating liposome. The long-circulating liposome provided by the invention comprises phospholipid, auxiliary lipid and poly carboxyl betaine lipid, wherein the long-circulating liposome and the preparation thereof can be applied to medicines for treating related diseases. According to the long-circulating liposome for avoiding the ABC phenomenon provided by the invention, the defect that a common liposome is easily recognized by a reticular endothelium system is overcome; a long-circulating effect of blood is reached; meanwhile, the ABC phenomenon caused by multiple intravenous injections of the PEG-modified long-circulating liposome is avoided; the medicine effect of a therapeutic medicine is effectively improved; and the long-circulating liposome has a high application prospect in the field of medicines.

The invention discloses a hand back vein injection instrument based on an infrared imaging technology. The injection instrument comprises a control panel, an infrared imaging part, a mechanical injection part, a fixed part and an instrument framework, wherein a horizontal adjusting rod in the mechanical injection part is parallel with two horizontal sliding rods, and is positioned above a center line position of a rectangle formed by four stepping motors; an injection rod is respectively connected with the horizontal adjusting rod and the horizontal sliding rods; 5 stepping motors are respectively connected with a stepping motor driving module; the stepping motor driving module is connected with a single chip microcomputer; the single chip microcomputer is connected with a computer through a digital serial port. The injection instrument is convenient for adjusting of the injection angle, greatly improves the injection stability of the injection rod, can help patients and medical care personnel to remove the interference of human factors, so as to rapidly and accurately accomplish vein injection, and improves the success rate of hand back vein puncture.

The invention discloses to an emulsion containing clevidipine and a preparation process and application thereof, relating to the emulsion utilizing the clevidipine and pharmaceutically acceptable salt or hydrate as active ingredients and the preparation process and the application thereof. The emulsion used for vein injection, which utilizes the clevidipine and the pharmaceutically acceptable salt or hydrate as the active ingredients, is formed by carrying out a certain preparation process on the active ingredients and pharmaceutically acceptable auxiliary materials, and can be used for rapid depressurization during and after a surgery. In the invention, the clevidipine and the pharmaceutically acceptable salt are taken as the active ingredients and some auxiliary materials with specific varieties and ratios are added, thus the emulsion for vein injection is developed according to the preparation process explained by the patent.

The invention discloses a culture method, application and a combined preparation of a hypoxia mesenchymal stem cell. By adopting an umbilical or placenta mesenchymal stem cell and combining the means of transfusing compound amino acid injection and the like, the vitality, the implantation survival rate and the treating effect of the mesenchymal stem cell in vivo can be improved; and in order to avoid the possibility of conglutination, conglomerating and cell mass embolism of the mesenchymal stem cell in blood vessel, the matching of saline containing heparin during treatment can be carried out by a mode of intravenous injection or intravenous drip. With more than three times of treatment, physical conditions of curee can be remarkably improved and objective indicators such as immunity, blood fat, blood sugar and the like can be remarkably improved.

The invention discloses an ambroxol hydrochloride injection with small volume and high stability and a preparation method thereof. In the ambroxol hydrochloride injection with small volume, the weightpercentage concentration of ambroxol hydrochloride is 0.3-4 percent, the ambroxol hydrochloride solution comprises a component capable of forming acid-base buffer pairs and further comprises carbon dioxide, and a part of space in an ampoule is filled with nitrogen gas. By utilizing carbon dioxide to remove oxygen from the solution, the invention provides the ambroxol hydrochloride injection whichhas small volume and longer stable phase and can be prepared by ambroxol hydrochloride material in different syntheticroutes. The ambroxol hydrochloride injection with small volume can be directly injected into a vein and has good buffering capacity for pH value of blood plasma.

The invention relates to a device for intravenous injection of a mouse tail and superficial intravenous injection of other parts. The device comprises a base, a transparent tube, a front fixing part and a rear fixing part, wherein a notch is formed in the rear fixing part, and ventilation holes are formed in two side edges of the transparent tube; the base is a closed cavity with a light source inside, the base comprises a top plate, a soleplate and four side plates, an adjustable light-transmitting operation panel which is hinged to the top plate is arranged between the side plate facing one end of the tail part of a mouse and the top plate, the side edge of the top plate is provided with a fixing plate facing the interior of the base, the adjustable light-transmitting operation panel is provided with an angle adjusting screw for adjusting an angle between the adjustable light-transmitting operation panel and the fixing plate, and other three side edges of the adjustable light-transmitting operation panel are respectively provided with an elastic light screening plate which is connected to the side edge of the adjacent base. By adopting the device, the safety of the operator is adequately guaranteed, and the operator can be prevented from being bitten by the mouse when in injection; moreover, the mouse is firmly fixed, the stress response of the mouse can be prevented from affecting the experiment result, and the experiment result is more reliable.

I.V. catheter assembly was a catheter with a distal needle for insertion into a blood vessel a portion of the catheter. An adapter with a self-sealing or self-closing plug is connected to the catheter, proximally of the distal needle. A proximal needle that can couple to the distal needle is in a guard tube on the other side of the plug. In use the proximal needle is pushed through the plug and into coupling engagement with the distal needle so the distal needle can be inserted into a blood vessel. The coupled needles are then withdrawn and shielded in the guard tube. The guard tube is then disconnected from the adapter and the adapter can be used to discharge blood from, or supply fluid to the blood vessel.

The invention relates to a drug delivery system for experimental animals, in particular to a tiny vein injection drug delivery system on body surfaces of experimental animals. The system comprises a fixed chamber 5 for experimental animals, a simple desk type magnifying glass, a vascular clamp 7 and an injector 1 with a superfine injection needle 2, wherein the fixed chamber 5 for experimental animals fixes experimental animals; the vascular clamp 7 is clamped above injection blood vessel; the injector 1 is connected with the superfine injection needle 2; the simple desk type magnifying glassis arranged above vein injection operation, and the injection can be carried out; and component parts of the device can be used solely or be in arbitrarily combined use according to actual operation requirement. The invention has the beneficial effect that the tiny vein injection process of experimental animals is more accurate, efficient, convenient and fast.

The invention discloses Doxofylline venous injection with a small volume and a preparation method thereof. The preparation unit of the isotonic small volume of doxofylline venous injection is 1-20ml,the weight percentage concentration of doxofylline is 1-4 percent, and the isotonic value of the venous injection is 257-340mosmol / kg. The invention enlarges the optional range of clinical applicationof doxofylline and provides the isotonic doxofylline venous injection with favorable security.

This invention is about a freeze-dried preparation using Llandeilo and its salt as active components and its making method and usages. It is a medicine composition that takes Llandeilo and its salt as active components, and is formed by mixing acceptable finding. It can be used to emergency cure tachycardia arrhythmia (containing atria fibrillation, atria flutter and sinus tachycardia) during operation. It uses Llandeilo and its salt as raw materials, adds some findings of specify kinds and proportions, and develop freeze-dried preparation according to this invention for intravenous injection.

The invention discloses a hollow lipid microfoam composition with fluorocarbon / nitrogen and preparing method, wherein the microfoam filming material is composed of phosphatide, protective and polymer; the phosphatide is selected from phosphatidyl Choline and phosphatidyl ethanolamine; the protective can be middle and macromolecular hydroxyethyl amidon; the polymer is selected from boluoshamu 188 or medically acceptable surface activator for vein injection; the lipid filming material covers the fluorocarbon liquid to form emulsion particle, which forms hollow lipid microball under high temperature instantaneously through gasifying the liquid fluorocarbon; the fluorocarbon / nitrogen is guided to produce the lipid microball for ultrasonic imaging with effectively reinforcing time over 60 min. The invention has high yield rate and fast manufacturing speed, which improves the microball dispersity and microball density effectively.

The present invention discloses a powder injection for intravenous injection for curing several diseases of liver damage with obvious therapeutic effect. Said powder injection has the action of protecting liver, its main component is silibinin-N-methylglucamine whose content is 20-500 mg / g.

An intravenous solution bag includes a temperature sensing device in the form of a temperature sensing strip. The strip includes a temperature scale and corresponding temperature sensitive substances that change color or illuminate the scale indicators to visually indicate solution temperature. The strip may be formed integral with the bag, may be attached to the bag exterior surface, may be laminated to the bag exterior surface or may be encased with the bag within a solution bag liner. Further, the temperature sensing strip may be affixed to bottles containing intravenous or other solutions, where the strip is attached to the bottle exterior surface or to a label affixed to the bottle to measure and indicate temperature of fluid contained therein as described above. Moreover, the temperature sensing strip may be employed by a receptacle or delivery tube of an infusion apparatus to measure and indicate solution temperature prior to or during infusion. In addition, the temperature sensing strip may be disposed within thermal treatment system compartments to measure and provide a visual indication of medical item temperatures. Alternatively, the strip may be employed by a stand, plate, receptacle or other structure receiving a medical item or container to provide a temperature measurement and indication as described above. The structure may be a stand-alone unit or may be attached to a thermal treatment or other system to facilitate temperature measurement.

The invention is a method which uses "the template method" to solve that it is difficult to write the medical record and prescription on the computer. each kind of disease name, the host sues, the present medical history, formerly history, the medical examination, and standard treating plan are inputted into the disease template databank in advance, each kind of medicine name, tablet, capsule, intermuscular injection, the vein injection, vein drip and other dosage-forms information are inputted into the data bank in advance. Through the computer procedure, only need several letters, and make a little change according to the reality, a serial of medical file can accomplished.

The present invention belongs to the field of biotechnology, and is one kind of brain targeting gene transfer and release system and its preparation process. Lactoferrin is first used to modify cationic polymer by means of hydrophilic polymer, and the modified cationic polymer is then compounded with plasmid DNA by means of electrostatic effect to form the gene transfer and release system. The present invention can raise the transfection efficiency and expression efficiency of gene on brain capillary endothelial cell effectively, and raise the brain targeting property of gene transfer and release system and the expression of the gene in brain obviously after the non-invasive administration via intravenous injection. Compared with available technology, the present invention has obviously raised brain targeting effect.

The invention provides a gastrodine injection, which comprises the forms of gastrodine water for injection and metal chelating agent, the invention also discloses its preparation and use. Wherein the preparation comprises depositing gastrodine with water, cold storing, ultrafiltration technology processing, and sterilizing. The injection can be used for treating brain trauma, megrims, nerve pain, cephalodynia and neurasthenia.

The invention provides a solid lipid nanoparticle or a solid liposome which is prepared from a raw material at least containing active medicines, a lipid carrier material, an effervescent acidic material and an effervescent alkaline material, wherein the lipid carrier material is a material in which active medicines are encapsulated. The medical lipid nanoparticle (the solid lipid nanoparticle or the solid liposome) is successfully prepared by virtue of an effervescent dispersion technology. The method is simple and convenient in preparation process, controllable in quality, low in equipment requirement and easy to industrialize. The lipid nanoparticle prepared according to the method can be in a solid state and in a mixed suspension state, is stable in quality and has the particle diameter within a range of 0.050-20 microns, and can be prepared into various solid-type and solution-type preparations so as to meet clinical medication requirements of oral administration, vein injection, inhalation and transdermal delivery.